ALPMY News and Press, Astellas Pharma Inc. ADR From 04/12/20

Deals and Financings Qiming closed its seventh China-focused US dollar fund with $1.1 billion for early stage Healthcare and TMT investments. Currently, Qiming manages nine US dollar funds and five RMB funds with $5.3 billion of assets under management. Despite the COVID-19 pandemic, Qimin...

TOKYO , April 9, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today a new drug application (NDA) for the oral once-daily therapy XOSPATA ® (gilteritinib), for the treatment of adult patients who have relapsed...

Quick Take Zentalis Pharmaceuticals ( ZNTL ) intends to raise $130 million from an IPO of its common stock, according to an amended S-1/A registration statement . The company is advancing a pipeline of potential drug treatments for breast cancer, solid tumors and other cancers. ZNTL has...

Today, we will see why Cytokinetics ( CYTK ) can be an attractive pick in 2020. Company overview Cytokinetics is a clinical-stage biotechnology company focused on developing innovative treatment options targeting cardiovascular and neuromuscular diseases caused due to impaired muscle fun...

Quick Take Zentalis Pharmaceuticals ( ZNTL ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of small molecule therapeutics targeting patients with breast cancer, solid tumors, blood cancers or l...

TOKYO and BOTHELL, Wash. , Feb. 19, 2020 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc . (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough T...

Biotech company FibroGen (NASDAQ: FGEN) announced Tuesday that its New Drug Application for drug candidate roxadustat, which treats anemia stemming from chronic kidney disease, has been accepted by the Food and Drug Administration. The regulator has fixed a Prescription Drug User Fee ...

Astellas (OTC: ALPMY) ,  Seattle Genetics   (NASDAQ: SGEN) , and  Merck (NYSE: MRK) have good news for new bladder cancer patients who aren't eligible for standard chemotherapy. Followup data from an ongoing clinical trial suggests that a combination of Padcev and Keytruda c...

TOKYO and NEW YORK , Feb. 11, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTA...

BOTHELL, Wash. and TOKYO , Feb. 10, 2020 /PRNewswire/ --  Seattle Genetics, Inc.  (Nasdaq: SGEN) and Astellas Pharma Inc.  (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced updated results from the phase 1b /2 clinical trial EV-103 in p...